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physical examinations. Under-diagnosis for PAD in prac-
tice was common and it might have under-estimated PAD
prevalence.
CONCLUSIONS: Previously reported PAD prevalence
varies depending on clinical presentations, different
screening tools, and the distribution of risks for PAD.
Understanding of and effectively adjusting for these
factors may be helpful to appropriately interpret and
utilize the study results for future research.
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OBJECTIVES: Recent analyses suggest that pulse pres-
sure is an important and independent risk factor for car-
diovascular disease. Accordingly, pulse pressure may also
be an important variable for inclusion in economic analy-
ses of hypertension therapy. We therefore analyzed the
relationship between pulse pressure and cardiovascular
events after adjustment for other risk factors to determine
if pulse pressure is an explanatory variable in the treat-
ment of hypertension. We then evaluated the importance
of pulse pressure as an explanatory variable in the treat-
ment of hypertension.
METHODS: Using multivariate analyses and data from
the Lipid Research Clinic Cohort, we examined the asso-
ciation between speciﬁc blood pressure measures and car-
diovascular death after adjustment for age and other risk
factors. We then compared the goodness of ﬁt (GOF =
[observed events–expected events]2) of various Markov
models to forecast the results of randomized clinical trials
of hypertension therapy using single blood measures or
combinations of measures.
RESULTS: Pulse pressure is a strong univariate risk factor
for coronary and cardiovascular death. Both pulse pres-
sure and diastolic blood pressure were independent (p <
0.05) risk factors with a signiﬁcant negative interaction
between increasing age and diastolic blood pressure and
a positive but non-signiﬁcant pulse pressure x age inter-
action. In Markov model simulations, the model in-
cluding diastolic and pulse pressure better approximated
(GOF = 91) the observed outcomes in ﬁve clinical trials
compared to either systolic, diastolic or pulse pressure
alone (GOF = 208, 375, 706 respectively).
CONCLUSION: Pulse pressure is a signiﬁcant indepen-
dent risk factor for cardiovascular events that increases
in relative importance with increasing age. When pulse
pressure is added to a Markov model with diastolic blood
pressure the results of clinical trials are more accurately
forecasted. Economic analyses of hypertension therapy
may be enhanced by considering blood pressure changes
other than only systolic or diastolic in isolation.
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OBJECTIVES: Cost of treatment for patients with the
same diagnosis can vary enormously due to differences in
comorbidities, practice patterns, and outcomes of care.
We sought to incorporate this variability in a model pro-
jecting the results of clinical trials to community practice.
METHODS: We modeled an episode of care for persons
hospitalized due to acute decompensated heart failure and
urgently treated with either nesiritide or dobutamine.
Patient characteristics and probability of signiﬁcant 
clinical events (cardiac arrest, sustained and non-
sustained ventricular tachycardia, hypotension, vomiting,
readmission and death during follow-up) were based on
pooled analysis of two completed clinical trials. The cost
of a hospital admission was derived from a subset of
records from the 1997 HCUP hospital database for dis-
charges with similar demographic and clinical features (n
= 57,223). Regressions were estimated for equations
explaining 1) hospital length of stay as a function of
patient attributes and speciﬁed clinical events; 2) the cost
of the admission as a function of patient attributes, clin-
ical events and predicted length of stay (LOS). For each
of 5000 simulated patients, the model ﬁrst stochastically
generates new sets of regression parameters using the
means and standard deviations of the original parameter
estimates. Next the model predicts patient demographic
characteristics and incidence of clinical events. The vector
of patient attributes is applied to the vectors of regression
parameters to predict LOS and then cost as a function of
predicted LOS.
RESULTS: This approach preserved distributional char-
acteristics of the original HCUP data (e.g. model pre-
dicted cost of admission vs. HCUP: mean 14,807 vs.
14,666; skew 2.94 vs. 3.16; kurtosis 10.03 vs. 11.43)
while enabling us to differentiate study drugs based on
incidence of clinical events.
CONCLUSIONS: The model yields robust estimates of
cost. Conﬁdence intervals surrounding point estimates
offer decision-makers a reliable basis for assessing 
potential ﬁnancial impact and uncertainty surrounding
adoption of the treatment intervention.
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